A New Citrated Formulation of Nalidixic Acid (Mictral® U.K.) for the Treatment of Acute Cystitis

1981 ◽  
Vol 9 (3) ◽  
pp. 177-180 ◽  
Author(s):  
C Dulake ◽  
G Adam ◽  
F Allenby ◽  
A R Anderson ◽  
A Clark-Jones ◽  
...  
Keyword(s):  
Side Effects ◽  
Nalidixic Acid ◽  
Acute Cystitis ◽  
Gram Negative ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis

A 3-day course of a new citrated formulation of nalidixic acid (Mictral) was assessed in fifty-four women presenting with acute uncomplicated cystitis. Over 96% of women with a significant Gram-negative bacteriuria were cured of the infection following a course of treatment. Only two relapses occurred in this group during the follow-up period. Relief of symptoms occurred in nearly 90% of infected patients and generally by the second day of treatment. Although the incidence of side-effects was about 20% they were not considered serious.

An Open Evaluation of a 3-Day Course of Pivmecillinam (Ten 200 mg Tablets) in Women with Acute Uncomplicated Cystitis

1980 ◽  
Vol 8 (2) ◽  
pp. 112-117 ◽  
Author(s):  
J F Donald ◽  
D M D Rimmer
Keyword(s):  
Side Effects ◽  
Clinical Response ◽  
Gram Positive ◽  
Gram Negative ◽  
Acute Uncomplicated Cystitis ◽  
Satisfactory Clinical Response ◽  
Gram Negative Organisms ◽  
Uncomplicated Cystitis ◽  
Gram Positive Cocci

One hundred and eighty-four women, with acute uncomplicated cystitis, received a 3-day course of pivmecillinam comprising an initial 400 mg (two tablets) dose, followed by 200 mg every 8 hours; a total of ten tablets. A satisfactory clinical response was achieved in 91% of patients. Bacteriological success was observed in 94% of sixty-eight patients with a proven infection. Side-effects were reported in sixteen patients (8.4%). Two patients ceased therapy prematurely. Pivmecillinam did not select out resistant Gram-negative organisms. A trend towards reinfection with Gram-positive cocci was observed. The possible significance of reinfection with different organisms is discussed.

scholarly journals General principles of uncomplicated cystitis therapy during pregnancy

2021 ◽  
pp. 121-126
Author(s):  
V. L. Tyutyunnik ◽  
N. E. Kan ◽  
L. V. Khachatryan
Keyword(s):  
Pregnant Women ◽  
Clinical Symptoms ◽  
Acute Cystitis ◽  
Microbiological Test ◽  
Fosfomycin Trometamol ◽  
Acute Uncomplicated Cystitis ◽  
Tract Infections ◽  
Uncomplicated Cystitis ◽  
Total Elimination

Urinary tract infections during pregnancy are associated with severe complications. Earlier initiation of antibiotic treatment for acute uncomplicated cystitis, reduces the various complications.Objective. To assess the effectiveness of fosfomycin in the treatment of acute uncomplicated cystitis during II and III trimester of pregnancy.Material and methods. The study included 74 pregnant women who had acute uncomplicated cystitis in II or III trimesters. All patients received fosfomycin trometamol 3.754 g (equivalent to 3 g fosfomycin) as antimicrobial therapy for acute uncomplicated cystitis. The drug was prescribed to 24 pregnant women in the II, and 50 in the III trimester of pregnancy.Results. After treatment with fosfomycin signs of acute cystitis gone in all patients. At the same time, regression of clinical symptoms was noted during the next days after therapy in 95.9% (n = 71) of cases. Repeated microbiological test of the middle portion of urine was performed 7 days after the end of antibiotic therapy. In 94.6% (n = 70) cases, total elimination of the pathogen was achieved. In 5.4% (n = 4) cases, there was a significant decrease of colonization Follow-up for three months showed the absence of recurrence of acute cystitis in all pregnant women who were included in the study.Conclusion. Fosfomycin is a highly effective drug in the treatment of uncomplicated cystitis during pregnancy.

Norfloxacin: A Quinoline Antibiotic

1986 ◽  
Vol 20 (4) ◽  
pp. 261-266 ◽  
Author(s):  
Dwight A. Marble ◽  
John A. Bosso
Keyword(s):  
Side Effects ◽  
Nalidixic Acid ◽  
Antimicrobial Agents ◽  
Bitter Taste ◽  
Gram Negative Bacteria ◽  
Third Generation ◽  
Gram Negative ◽  
Intravenous Antibiotics ◽  
Third Generation Cephalosporins ◽  
Quinolinecarboxylic Acid

Norfloxacin is a quinoline (quinolinecarboxylic acid) that should prove successful in treating infections that currently require hospitalization and intravenous antibiotics. Although a nalidixic acid derivative, it possesses greater antibacterial activity against gram-positive and gram-negative bacteria. Compared with other antimicrobial agents, norfloxacin is more potent than the aminoglycosides, first-, second-, and third-generation cephalosporins, tetracycline, trimethoprim-sulfamethoxazole, carbenicillin, piperacillin, nalidixic acid, oxolinic acid, cinoxacin, and enoxacin. In the clinical studies to date, the side effects of norfloxacin have been minimal, but include nausea, vomiting, anorexia, dizziness, headache, drowsiness, depression, and a bitter taste in the mouth. In studies with more than 4000 patients, the incidence of side effects ranged from 3.9 to 4.7 percent, with most appearing by the second day of therapy.

scholarly journals Greek Version of the Acute Cystitis Symptom Score. Part I: Linguistic Validation

2020 ◽  
Author(s):  
Konstantinos Stamatiou ◽  
Evangelia Samara ◽  
Jakhongir F. Alidjanov ◽  
Kurt G. Naber ◽  
Adrian Pilatz ◽  
...  
Keyword(s):  
Symptom Score ◽  
Healthcare Professionals ◽  
American English ◽  
Greek Version ◽  
Linguistic Validation ◽  
Acute Cystitis ◽  
Original Language ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis ◽  
Self Reporting Questionnaire

Objective: The Acute Cystitis Symptom Score (ACSS) was developed and validated as a self-reporting questionnaire for diagnosing and monitoring acute, uncomplicated cystitis (AC) in female patients. The study aims at the translation of the ACSS into Greek from original Russian as a source and American English as a new master version and at its linguistic validation. Material and Methods: Three independent professional native Greek translators, two of them experts in Russian and one in English, translated the ACSS from Russian and American English into Greek. The second group of three translators translated each of the three versions back into the original language to detect or correct any important discrepancies. These three Greek versions were then used for linguistic validation. Results: The English to Greek translation reflected more the spoken language, the two Russian to Greek translations more the written, formal language. A total of 60 randomly selected females and 30 healthcare professionals was asked about their preferences and to comment on each of the three translations. Considering all comments the scientific committee (SC) developed the Greek consensus version. For cognitive assessment additional 30 healthcare professionals and 30 females were asked to comment on the intelligibility of all items. Considering their comments the linguistically validated Greek study version was established by the SC. Conclusion: The linguistically validated Greek version of the ACSS can now be used for the clinical validation study.

scholarly journals Validation of the American English Acute Cystitis Symptom Score

Antibiotics ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 929
Author(s):  
Jakhongir F. Alidjanov ◽  
Kurt G. Naber ◽  
Adrian Pilatz ◽  
Florian M. Wagenlehner
Keyword(s):  
Symptom Score ◽  
Clinical Success ◽  
American English ◽  
Clinical Success Rate ◽  
Acute Cystitis ◽  
Sum Score ◽  
Patient Reported ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis ◽  
Self Reporting Questionnaire

The diagnosis of acute uncomplicated cystitis (UC) is usually based on clinical symptoms. The study aims to develop and validate the American-English Acute Cystitis Symptom Score (ACSS), a self-reporting questionnaire for diagnosis and patient-reported outcome in women with acute uncomplicated cystitis (UC). After certified translation into American-English and cognitive assessment, the clinical validation of the ACSS was performed embedded in a US phase-II trial. 167 female patients with typical symptoms of UC were included in the study following US Food and Drug Administration (FDA) guidance. At Day 1 (diagnosis), the mean (SD) sum score of the six ACSS typical symptoms reached 10.60 (2.51). Of 100 patients followed-up last time on Day 5 or 6 (End-of-treatment, EoT), 91 patients showed clinical success according to the favored ACSS criteria (sum score of typical symptoms 0.98 (1.94)). There was no correlation between the severity of symptoms on Day 1 or between clinical success rate at EoT and level of bacteriuria on Day 1. The American-English ACSS showed high predictive ability and responsiveness and excellent levels of reliability and validity. It can now be recommended as the new master version in clinical and epidemiological studies, in clinical practice, or for self-diagnosis of women with symptoms of UC.

scholarly journals Uropathogen Antibiotic Resistance in Adult Women Presenting to Family Physicians with Acute Uncomplicated Cystitis

2004 ◽  
Vol 15 (5) ◽  
pp. 266-270 ◽  
Author(s):  
Warren J McIsaac ◽  
Tony Mazzulli ◽  
Rahim Moineddin ◽  
Janet Raboud ◽  
Susan Ross
Keyword(s):  
Antibiotic Resistance ◽  
Family Physicians ◽  
Empirical Treatment ◽  
Western Canada ◽  
Adult Women ◽  
Eastern Canada ◽  
Acute Cystitis ◽  
Exact Test ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis

BACKGROUND: Increasing rates of trimethoprim-sulfamethoxazole (TMP-SMX) resistance among uropathogens have raised concerns about its continued role in empirical treatment of acute uncomplicated cystitis in adult women.OBJECTIVES: To determine current rates of antibiotic resistance among uropathogens in the community.METHOD: Urine culture reports from adult women with symptoms of cystitis attending the offices of family physicians from across Canada were examined. Antibiotic sensitivities and the total number of antibiotics an organism was resistant to was determined.RESULTS: In 446 women, 235 (61.4%) positive urine cultures were identified. Of these, 38.2% were resistant to at least one antibiotic and 21.5% were resistant to two or more antibiotics. The rate of ampicillin resistance was 34.1%. For TMP-SMX, resistance was reported in 10.8% of samples. Antibiotic resistance was higher in British Columbia (55%) and western provinces (48%), compared with Ontario (33.3%) and the eastern provinces (26.3%, P=0.04, Fisher's exact test). Multidrug resistance was also higher in western Canada (33.9%) than in eastern Canada (16.6%, P=0.007).CONCLUSIONS: TMP-SMX resistance in Canada remains within current recommended guidelines, allowing for its continued use as a first line empirical treatment for acute cystitis in adult women. The reasons for higher rates of antibiotic resistance in western Canada merit further study.

scholarly journals Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II

2019 ◽  
Vol 38 (8) ◽  
pp. 1977-1988 ◽  
Author(s):  
J. F. Alidjanov ◽  
K. G. Naber ◽  
A. Pilatz ◽  
A. Radzhabov ◽  
M. Zamuddinov ◽  
...  
Keyword(s):  
Clinical Cure ◽  
Missing Values ◽  
Patient Reported Outcome Measures ◽  
Patient Reported Outcome ◽  
Summary Score ◽  
Acute Cystitis ◽  
Female Patients ◽  
Patient Reported ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis

Abstract Purpose Since symptomatic, non-antibiotic therapy has become an alternative approach to treat acute cystitis (AC) in women, suitable patient-reported outcome measures (PROM) are urgently needed. The aim of this part II of a larger non-interventional, case–control study was the additional assessment of the ACSS as a suitable PROM. Methods Data from 134 female patients with diagnosed acute uncomplicated cystitis were included in the current analysis with (1) a summary score of “Typical” domain of 6 and more; (2) at least one follow-up evaluation after the baseline visit; (3) no missing values in the ACSS questionnaire data. Six different predefined thresholds based on the scoring of the ACSS items were evaluated to define “clinical cure”, also considering the draft FDA and EMA guidelines. Results Of the six different thresholds tested, a summary score of the five typical symptoms of 5 and lower with no symptom more than 1 (mild), without visible blood in urine, with or without including QoL issues was favoured, which partially also could be adapted to the draft FDA and EMA guidelines. The overall patient’s clinical assessment (“Dynamic” domain) alone was not sensitive enough for a suitable PROM. Conclusions Scoring of the severity of symptoms is needed not only for diagnosis, but also for PROM to define “clinical cure” of any intervention, which could be combined with QoL issues. Results of the study demonstrated that the ACSS questionnaire has the potential to be used as a suitable PROM and should further be tested in prospective clinical studies.

A General Practice Evaluation of Selexid Suspension as a Treatment for Acute Urinary Tract Infection

1982 ◽  
Vol 10 (1) ◽  
pp. 35-38 ◽  
Author(s):  
I C Murison ◽  
Dileas M Sweetenham
Keyword(s):  
General Practice ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Side Effects ◽  
Tract Infection ◽  
Cure Rate ◽  
Bacteriological Cure ◽  
Acute Uncomplicated Cystitis ◽  
Uncomplicated Cystitis ◽  
Acute Urinary Tract Infection

Fifty-seven general practice patients (fifty-five females and two males) with acute uncomplicated cystitis received a 5-day course of pivmecillinam suspension at a dose of 200 mg (2 sachets) three times a day. Positive bacteriological cultures were obtained from twenty-eight patients (49%) before treatment. The bacteriological cure rate was 100%. All patients experienced some relief of symptoms and thirty nine patients (68%) were completely symptom-free after treatment. Selexid suspension was generally well tolerated. Side effects were reported in only four patients (6%) and no patient had to stop treatment prematurely.

Sign in / Sign up

Export Citation Format

Share Document